Mereo BioPharma Group PLC (MREO)
3.68
+0.10
(+2.79%)
USD |
NASDAQ |
Nov 21, 16:00
3.675
0.00 (0.00%)
After-Hours: 20:00
Mereo BioPharma Group Enterprise Value: 495.96M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 495.96M |
| November 20, 2024 | 480.45M |
| November 19, 2024 | 466.49M |
| November 18, 2024 | 441.66M |
| November 15, 2024 | 472.69M |
| November 14, 2024 | 517.69M |
| November 13, 2024 | 553.37M |
| November 12, 2024 | 561.13M |
| November 11, 2024 | 589.05M |
| November 08, 2024 | 584.20M |
| November 07, 2024 | 557.89M |
| November 06, 2024 | 559.44M |
| November 05, 2024 | 559.44M |
| November 04, 2024 | 545.51M |
| November 01, 2024 | 587.29M |
| October 31, 2024 | 576.46M |
| October 30, 2024 | 582.65M |
| October 29, 2024 | 576.46M |
| October 28, 2024 | 574.91M |
| October 25, 2024 | 584.20M |
| October 24, 2024 | 598.12M |
| October 23, 2024 | 582.65M |
| October 22, 2024 | 601.22M |
| October 21, 2024 | 625.98M |
| October 18, 2024 | 639.90M |
| Date | Value |
|---|---|
| October 17, 2024 | 630.62M |
| October 16, 2024 | 622.88M |
| October 15, 2024 | 627.52M |
| October 14, 2024 | 616.69M |
| October 11, 2024 | 596.58M |
| October 10, 2024 | 562.54M |
| October 09, 2024 | 565.63M |
| October 08, 2024 | 568.72M |
| October 07, 2024 | 582.65M |
| October 04, 2024 | 605.86M |
| October 03, 2024 | 605.86M |
| October 02, 2024 | 588.84M |
| October 01, 2024 | 570.27M |
| September 30, 2024 | 560.99M |
| September 27, 2024 | 554.45M |
| September 26, 2024 | 548.30M |
| September 25, 2024 | 532.91M |
| September 24, 2024 | 540.60M |
| September 23, 2024 | 546.76M |
| September 20, 2024 | 571.37M |
| September 19, 2024 | 575.99M |
| September 18, 2024 | 566.76M |
| September 17, 2024 | 525.22M |
| September 16, 2024 | 609.84M |
| September 13, 2024 | 575.99M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-69.32M
Minimum
May 11 2022
666.76M
Maximum
Aug 26 2024
184.44M
Average
124.65M
Median
Enterprise Value Benchmarks
| NuCana PLC | -11.87M |
| TC BioPharm (Holdings) PLC | -0.927M |
| Biodexa Pharmaceuticals PLC | -3.355M |
| Adaptimmune Therapeutics PLC | 26.67M |
| Bicycle Therapeutics PLC | 508.01M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -15.00M |
| Total Expenses (Quarterly) | 9.147M |
| EPS Diluted (Quarterly) | -0.10 |
| Earnings Yield | -8.15% |